These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 36810738)

  • 1. Endogenous retroviruses and TDP-43 proteinopathy form a sustaining feedback driving intercellular spread of Drosophila neurodegeneration.
    Chang YH; Dubnau J
    Nat Commun; 2023 Feb; 14(1):966. PubMed ID: 36810738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous retroviruses can propagate TDP-43 proteinopathy.
    Ferreiro ME; Faulkner GJ
    Trends Neurosci; 2023 Jun; 46(6):413-414. PubMed ID: 37061454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Gypsy Endogenous Retrovirus Drives Non-Cell-Autonomous Propagation in a Drosophila TDP-43 Model of Neurodegeneration.
    Chang YH; Dubnau J
    Curr Biol; 2019 Oct; 29(19):3135-3152.e4. PubMed ID: 31495585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TDP-43 proteinopathy in ALS is triggered by loss of ASRGL1 and associated with HML-2 expression.
    Garcia-Montojo M; Fathi S; Rastegar C; Simula ER; Doucet-O'Hare T; Cheng YHH; Abrams RPM; Pasternack N; Malik N; Bachani M; Disanza B; Maric D; Lee MH; Wang H; Santamaria U; Li W; Sampson K; Lorenzo JR; Sanchez IE; Mezghrani A; Li Y; Sechi LA; Pineda S; Heiman M; Kellis M; Steiner J; Nath A
    Nat Commun; 2024 May; 15(1):4163. PubMed ID: 38755145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling TDP-43 proteinopathy in Drosophila uncovers shared and neuron-specific targets across ALS and FTD relevant circuits.
    Godfrey RK; Alsop E; Bjork RT; Chauhan BS; Ruvalcaba HC; Antone J; Gittings LM; Michael AF; Williams C; Hala'ufia G; Blythe AD; Hall M; Sattler R; Van Keuren-Jensen K; Zarnescu DC
    Acta Neuropathol Commun; 2023 Oct; 11(1):168. PubMed ID: 37864255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy.
    Khalil B; Chhangani D; Wren MC; Smith CL; Lee JH; Li X; Puttinger C; Tsai CW; Fortin G; Morderer D; Gao J; Liu F; Lim CK; Chen J; Chou CC; Croft CL; Gleixner AM; Donnelly CJ; Golde TE; Petrucelli L; Oskarsson B; Dickson DW; Zhang K; Shorter J; Yoshimura SH; Barmada SJ; Rincon-Limas DE; Rossoll W
    Mol Neurodegener; 2022 Dec; 17(1):80. PubMed ID: 36482422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Molecular Link Between TDP-43, Endogenous Retroviruses and Inflammatory Neurodegeneration in Amyotrophic Lateral Sclerosis: a Potential Target for Triumeq, an Antiretroviral Therapy.
    Dubowsky M; Theunissen F; Carr JM; Rogers ML
    Mol Neurobiol; 2023 Nov; 60(11):6330-6345. PubMed ID: 37450244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis?
    Vanden Broeck L; Callaerts P; Dermaut B
    Trends Mol Med; 2014 Feb; 20(2):66-71. PubMed ID: 24355761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of TDP-43 Proteinopathy Onset and Propagation.
    Chen HJ; Mitchell JC
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A feedback loop between dipeptide-repeat protein, TDP-43 and karyopherin-α mediates C9orf72-related neurodegeneration.
    Solomon DA; Stepto A; Au WH; Adachi Y; Diaper DC; Hall R; Rekhi A; Boudi A; Tziortzouda P; Lee YB; Smith B; Bridi JC; Spinelli G; Dearlove J; Humphrey DM; Gallo JM; Troakes C; Fanto M; Soller M; Rogelj B; Parsons RB; Shaw CE; Hortobágyi T; Hirth F
    Brain; 2018 Oct; 141(10):2908-2924. PubMed ID: 30239641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43.
    Mann JR; Gleixner AM; Mauna JC; Gomes E; DeChellis-Marks MR; Needham PG; Copley KE; Hurtle B; Portz B; Pyles NJ; Guo L; Calder CB; Wills ZP; Pandey UB; Kofler JK; Brodsky JL; Thathiah A; Shorter J; Donnelly CJ
    Neuron; 2019 Apr; 102(2):321-338.e8. PubMed ID: 30826182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration.
    Gao J; Wang L; Yan T; Perry G; Wang X
    Mol Cell Neurosci; 2019 Oct; 100():103396. PubMed ID: 31445085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stathmin-2: adding another piece to the puzzle of TDP-43 proteinopathies and neurodegeneration.
    Glass JD
    J Clin Invest; 2020 Nov; 130(11):5677-5680. PubMed ID: 33074248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia.
    Pasetto L; Grassano M; Pozzi S; Luotti S; Sammali E; Migazzi A; Basso M; Spagnolli G; Biasini E; Micotti E; Cerovic M; Carli M; Forloni G; De Marco G; Manera U; Moglia C; Mora G; Traynor BJ; Chiò A; Calvo A; Bonetto V
    Brain; 2021 Dec; 144(12):3710-3726. PubMed ID: 34972208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD.
    Kumar S; Phaneuf D; Cordeau P; Boutej H; Kriz J; Julien JP
    Mol Neurodegener; 2021 Jan; 16(1):1. PubMed ID: 33413517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optogenetic TDP-43 nucleation induces persistent insoluble species and progressive motor dysfunction in vivo.
    Otte CG; Fortuna TR; Mann JR; Gleixner AM; Ramesh N; Pyles NJ; Pandey UB; Donnelly CJ
    Neurobiol Dis; 2020 Dec; 146():105078. PubMed ID: 32927062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear transport dysfunction: a common theme in amyotrophic lateral sclerosis and frontotemporal dementia.
    Jovičić A; Paul JW; Gitler AD
    J Neurochem; 2016 Aug; 138 Suppl 1():134-44. PubMed ID: 27087014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both cytoplasmic and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies.
    Miguel L; Frébourg T; Campion D; Lecourtois M
    Neurobiol Dis; 2011 Feb; 41(2):398-406. PubMed ID: 20951205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TDP-43 pathology: From noxious assembly to therapeutic removal.
    Keating SS; San Gil R; Swanson MEV; Scotter EL; Walker AK
    Prog Neurobiol; 2022 Apr; 211():102229. PubMed ID: 35101542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.
    Hayes LR; Kalab P
    Neurotherapeutics; 2022 Jul; 19(4):1061-1084. PubMed ID: 35790708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.